COMMUNIQUÉS West-GlobeNewswire

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
14/09/2026
Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS [...]
Wellthy Acquires Cleo as Two Leaders Come Together to Create the Singular Platform for Family Care
14/09/2026
Wellthy's acquisition of Cleo brings together two leaders in family care, expanding support for employers, health plans, and families. NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Wellthy today announced its acquisition [...]
Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)
14/09/2026
Company announcement No. 48 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) Copenhagen, Denmark, September 14, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq [...]
Paralyzed Marine Veteran Stands and Walks at Enjoy Illinois 300 as Patriot Mobile Puts SoldierStrong on Ty Dillon's No. 10
14/09/2026
STAMFORD, Conn., Sept. 14, 2026 (GLOBE NEWSWIRE) -- SoldierStrong, the national nonprofit committed to delivering revolutionary medical technologies to America's veterans, brought its mission to the NASCAR Cup Series [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 37 - 2026
14/09/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 7 septembre au 11 septembre 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2026
14/09/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 7th September to 11th September 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial [...]
GENFIT engage un programme de développement clinique de phase 2 avec Nangibotide dans l’ACLF
14/09/2026
L’acquisition par GENFIT du nangibotide, un candidat-médicament au profil différencié en phase avancée de développement clinique, renforce le portefeuille de thérapies innovantes de la Société adressant d’importants [...]
GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF
14/09/2026
GENFIT's acquisition of nangibotide, a differentiated late-stage asset, reinforces the Company’s portfolio of innovative therapies addressing high unmet medical needs The investigation in Phase 2 is supported by a [...]
KFSH Riyadh Records Zero High-Risk Findings Across Nearly 1,800 Measures in JCI Reaccreditation
14/09/2026
RIYADH, Saudi Arabia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) in Riyadh has secured reaccreditation as an Academic Medical Center from Joint Commission International [...]
Quiet Communities and Science for Georgia Release First-of-its-Kind Study on the Impacts of Data Center and Cryptomining Noise
14/09/2026
New national survey documents widespread reports of persistent noise and disrupted quality of life as AI data centers and cryptomines rapidly expand across the United States LINCOLN, Mass. and ATLANTA, Sept. 14, 2026 ( [...]
CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
14/09/2026
Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition CINCINNATI, [...]
Glass House Brands Releases Mama Sue Professional Athlete Balm for Sale in California
14/09/2026
New high-potency transdermal balm was created with professional athletes in mind and is suitable for both high-performance recovery and everyday use LONG BEACH, Calif. and TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) -- [...]
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
14/09/2026
Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is October 2, 2026 SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE [...]
Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm
14/09/2026
Mint features a new and innovative patch pump architecture Full Mint U.S. commercialization expected to begin in Q1 2027 Manufacturing capacity expected to produce at least 1.5 million disposable Mint units during 2027 [...]
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
14/09/2026
Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor Seventh consecutive positive DSMB recommendation reinforces [...]
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
14/09/2026
Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies The unique capabilities of AI- [...]
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
14/09/2026
Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Akebia [...]
Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting
14/09/2026
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint Meeting with FDA planned on October 1 st to align on RAD101Phase 3 pivotal trial protocol Brain [...]
Leios Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for 10XB-101 for Moderate-to-Severe Submental Fat Fullness
14/09/2026
Alignment Reached on Key Elements of the Phase 3 Program to Support a 505(b)(2) NDA Submission 10XB-101 Now has Clear Regulatory Path Forward LA JOLLA, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Leios Therapeutics (“ [...]

Pages